



30th May, 2019

To,
BSE limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai- 400001

Dear Sir,
Scrip Code: 541299

Sub: Audited Financial Results for the half year and year ended March 31, 2019

In continuation of our Letter dated May 23, 2019, we wish to inform you that the Board of the Company at its meeting held today, inter alia has transacted the following:

- a) The Board has approved the Audited Financial Results for the half year and year ended March 31, 2019.

Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we enclose the following:

- i. Statement showing Audited Financial Results for the half year and year ended March 31, 2019.
- ii. Auditors Report on Financial Results of the Company for the year ended 31st March, 2019.

Kindly take the same on record and acknowledge.

Thank You
Yours Faithfully

For Dr Lalchandani Labs Limited



Arjan Lalchandani
Managing Director
DIN-07014579





Jain Agarwal & Company

Chartered Accountants

Auditor's Report on Half Yearly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of
Dr Lalchandani Labs Limited

We have audited the accompanying financial results of Dr Lalchandani Labs Limited ('the Company') for the year ended March 31, 2019, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


This half yearly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statement, which are the responsibility of the company's management and approved by the Board of Directors. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25/ Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally acceptable in India. Those standards requires that we plan and perform the audit to obtain reasonable assurance as to whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial result. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our audit.

In our opinion and to the best of our information and according to the explanations given to us these half yearly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii. give a true and fair view of the net profit and other financial information of the company for the year ended 31st March, 2019

For Jain Agarwal & Company,
Chartered Accountants
FRN No. 024866N


CA Karan Jain
Partner
M.No- 521992

Place: New Delhi
Date: 30th May, 2019



AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED AND THE YEAR ENDED 31ST MARCH, 2019

Amount Rs. in Lacs

Sr. No.	Particulars	Half Year Ended			For the Year Ended	Previous Year Ended
		31.03.2019	30.09.2018	31.03.2018	31.03.2019	31.03.2018
		Audited	Un-audited	Audited	Audited	Audited
I	Revenue from Operations	264.14	261.70	229.59	526.10	494.45
II	Other Income	0.57	-	1.78	0.57	2.70
III	Total Revenue (I+II)	264.71	261.70	231.37	526.67	497.15
IV	Expenses					
	(a) Cost of materials consumed	21.60	62.74	50.03	60.57	110.17
	(b) Purchases of stock in trade	32.50	40.15	54.21	72.65	112.44
	(c) Changes in inventories of finished goods, work in progress and stock in trade	10.90	1.18	4.18	12.08	2.27
	(d) Employee benefits expense	43.05	41.79	41.91	94.59	70.78
	(e) Finance Cost	4.59	8.87	12.45	13.63	26.19
	(f) Depreciation and amortisation expense	19.67	15.22	13.08	34.89	13.08
	(g) Other Expenses	130.27	106.72	98.35	251.09	159.57
	Total Expenses	219.18	235.34	215.82	454.77	379.79
V	Profit before exceptional and extraordinary items and tax (III - IV)	45.53	26.36	15.55	71.90	117.36
VI	Exceptional Items	-	-	-	-	-
VII	Profit extraordinary items and tax (V - VI)	45.53	26.36	15.55	71.90	117.36
VIII	Extraordinary Items	-	-	-	-	-
IX	Profit before tax (VII - VIII)	45.53	26.36	15.55	71.90	117.36
X	Tax Expenses :					
	(1) Current Tax	8.92	6.85	6.83	15.77	32.14
	(2) Deferred Tax	2.78	-	2.39	2.78	2.39
XI	Profit / (Loss) from Period from continuing operations (VII - VIII)	33.84	19.51	6.33	53.35	82.83
XII	Profit (Loss) from discontinuing Operations	-	-	-	-	-
XIII	Tax Expense of Discontinuing operations	-	-	-	-	-





AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED AND THE YEAR ENDED 31ST MARCH, 2019

Amount Rs. in Lacs

Sr. No.	Particulars	Half Year Ended			For the Year Ended	
		31.03.2019	30.09.2018	31.03.2018	31.03.2019	31.03.2018
		Audited	Un-audited	Audited	Audited	Audited
XIV	Profit / (Loss) from Discontinuing operations (After Tax XII- XIII)	-	-	-	-	-
XV	Profit (Loss) for the period (XI +XIV)	33.84	19.51	6.33	53.35	82.83
XVI	Earnings Per Share of Rs. 10 Each (Not Annualised)					
	(a) Basic (Rs.)	0.78	0.45	0.22	1.23	2.82
	(b) Diluted (Rs.)	0.78	0.45	0.22	1.23	2.82

Notes:

1. The financial results were reviewed by the audit committee and approved by the Board of directors at its meeting held on May 30, 2019.
2. There were no investor complaints received / pending as at 31st March, 2019
3. The company does not have more than one reportable segment in terms of AS-17 Issued by ICAI. Hence segment wise reporting is not applicable.
4. The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary.

For Dr Lalchandani Labs Limited



(Dr. Arjan Lalchandani)
Managing Director (DIN: 07014579)
New Delhi
30-May-19





STANDALONE STATEMENT OF ASSETS AND LIABILITIES

Amount in Rs. Lacs

Sr. No.	Particulars	For the Year Ended	
		31.03.2019	31.03.2018
1	Shareholders' Funds		
	(a) Share Capital	433.31	293.31
	(b) Reserves and Surplus	373.33	39.98
	(c) Money received against share warrants	-	-
	Sub-total-Shareholders' Funds	806.64	333.29
2	Share application money pending allotment		
3	Non Current Liabilities		
	(a) Long Term Borrowings	85.46	182.37
	(b) Deferred Tax Liability	5.17	2.39
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	Sub-total-Non Current Liabilities	90.62	184.76
4	Current Liabilities		
	(a) Short Term Borrowings	5.00	5.06
	(b) Trade Payables	64.60	68.17
	(c) Other Current Liabilities	28.10	21.87
	(d) Short Term Provisions	15.77	7.03
	Sub-total-Current Liabilities	113.47	102.13
	TOTAL EQUITY AND LIABILITIES	1,010.74	620.18
II	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible assets	312.12	205.36
	(ii) Intangible assets	15.91	0.45
	(b) Non Current Investments	24.10	24.10
	(c) Long Term Loans & Advances	31.75	-
	(d) Other Non Current Assets	45.74	8.25
	Sub-total-Non Current Assets	429.61	238.16





STANDALONE STATEMENT OF ASSETS AND LIABILITIES

Amount in Rs. Lacs

Sr. No.	Particulars	For the Year Ended	
		31.03.2019	31.03.2018
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	39.21	27.12
	(c) Trade Receivables	180.70	112.06
	(d) Cash & cash equivalents	202.40	90.86
	(e) Short Term Loans & Advances	105.24	107.89
	(f) Other Current Assets	53.57	44.09
	Sub-total-Current Assets	581.13	382.02
	TOTAL ASSETS	1,010.74	620.18

For Dr Lalchandani Labs Limited



Dr. Arjan Lalchandani
(Managing Director DIN: 07014579)

New Delhi
30-May-19

